Expression of SSR1 in melanoma - The Human Protein Atlas

We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.

SUMMARY

TISSUE

BRAIN

SINGLE CELL

SUBCELL

CANCER

BLOOD

CELL LINE

STRUCTURE

INTERACTION

SSR1

SKIN CUTANEOUS MELANOMA (TCGA) - Interactive survival scatter plotⁱ

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisⁱ

SSR1 is not prognostic in Skin Cutaneous Melanoma (TCGA)

Stage:

Survival analysis

Current cut offⁱ :

Best expression cut offⁱ : 112.25

Median expressionⁱ : 75.43

Median follow up timeⁱ : 1.23

P scoreⁱ 0.074

3-year survival highⁱ 0%

3-year survival lowⁱ 49%

TCGA RNA samplesⁱ

Average pTPM

90.0

Number of samples

99

Samples

Sample	Description	pTPM
TCGA-GF-A769-01A	39 years, male, white, stage:Stage IIC, dead, 1070 days	265.6
TCGA-EB-A5FP-01A	65 years, female, white, stage:Stage IV, dead, 454 days	218.3
TCGA-BF-AAP6-01A	55 years, male, white, stage:Stage III, alive, 325 days	203.2
TCGA-BF-A5EP-01A	75 years, female, white, stage:Stage IIIC, alive, 335 days	196.4
TCGA-EB-A3XF-01A	57 years, male, white, stage:Stage IIC, alive, 278 days	190.2
TCGA-FS-A1ZN-01A	43 years, male, white, stage:Stage IIIA, dead, 730 days	184.8
TCGA-EB-A6QY-01A	71 years, male, white, stage:Stage IIC, alive, 382 days	181.2
TCGA-EB-A44O-01A	69 years, male, white, stage:Stage IIB, alive, 81 days	169.2
TCGA-EB-A82C-01A	70 years, female, asian, stage:Stage IIC, alive, 17 days	168.4
TCGA-BF-A3DM-01A	63 years, male, white, stage:Stage IIA, alive, 601 days	166.2
TCGA-FR-A2OS-01A	49 years, female, white, stage:Stage IIC, dead, 368 days	163.8
TCGA-EB-A24C-01A	56 years, male, white, stage:'--, alive, 632 days	162.6
TCGA-EB-A5SE-01A	73 years, male, white, stage:Stage IIB, dead, 401 days	158.6
TCGA-BF-A3DJ-01A	36 years, female, white, stage:Stage IIIB, alive, 464 days	150.4
TCGA-ER-A19T-01A	51 years, male, white, stage:Stage IV, dead, 270 days	147.6
TCGA-EB-A431-01A	34 years, male, white, stage:Stage IIC, alive, 568 days	145.6
TCGA-GF-A2C7-01A	48 years, male, white, stage:Stage IIC, alive, 21 days	142.8
TCGA-EB-A551-01A	78 years, female, white, stage:Stage IIIC, alive, 590 days	141.8
TCGA-EB-A24D-01A	72 years, male, white, stage:Stage IIIB, alive, 645 days	136.9
TCGA-BF-A1PV-01A	74 years, female, white, stage:Stage IIC, alive, 14 days	135.4
TCGA-BF-A3DN-01A	81 years, female, white, stage:Stage IIIC, alive, 717 days	133.7
TCGA-BF-AAP1-01A	86 years, male, white, stage:Stage IIC, alive, 409 days	132.8
TCGA-EB-A5VU-01A	56 years, male, asian, stage:Stage IIIB, dead, 321 days	130.3
TCGA-ER-A42H-01A	76 years, male, white, stage:'--, dead, 426 days	130.0
TCGA-EB-A3XB-01A	63 years, male, white, stage:Stage II, alive, 796 days	128.1
TCGA-EB-A44N-01A	59 years, male, white, stage:Stage IIC, dead, 205 days	120.9
TCGA-BF-A1Q0-01A	80 years, male, white, stage:Stage IIC, alive, 831 days	117.7
TCGA-FR-A3R1-01A	69 years, male, white, stage:Stage IIC, alive, 685 days	115.4
TCGA-EB-A51B-01A	53 years, male, white, stage:Stage IIC, alive, 931 days	114.8
TCGA-ER-A19K-01A	79 years, female, white, stage:Stage IIC, dead, 469 days	114.6
TCGA-GN-A263-01A	24 years, male, white, stage:Stage IV, dead, 467 days	114.2
TCGA-EB-A6R0-01A	58 years, female, white, stage:Stage IIC, dead, 608 days	113.7
TCGA-FW-A5DX-01A	71 years, male, white, stage:Stage IIIC, alive, 640 days	110.8
TCGA-EB-A4IS-01A	77 years, male, white, stage:Stage IIB, alive, 774 days	107.0
TCGA-D9-A3Z4-01A	54 years, male, white, stage:Stage IIIC, dead, 519 days	106.4
TCGA-D9-A4Z5-01A	68 years, male, white, stage:Stage IIB, alive, 218 days	105.4
TCGA-EB-A3XC-01A	74 years, male, white, stage:Stage IIC, alive, 650 days	104.8
TCGA-BF-AAP7-01A	76 years, female, white, stage:Stage IIC, alive, 318 days	97.8
TCGA-ER-A196-01A	64 years, female, white, stage:Stage IIC, alive, 1785 days	94.4
TCGA-BF-A1PU-01A	46 years, female, white, stage:Stage IIC, alive, 387 days	88.5
TCGA-BF-A1PZ-01A	71 years, female, white, stage:Stage IIB, alive, 853 days	87.4
TCGA-D9-A4Z2-01A	50 years, male, white, stage:Stage IIIC, dead, 190 days	87.2
TCGA-EB-A44P-01A	58 years, female, white, stage:Stage IIC, alive, 741 days	86.8
TCGA-BF-A1PX-01A	56 years, male, white, stage:Stage IIIB, dead, 282 days	86.8
TCGA-BF-A5ES-01A	76 years, female, white, stage:Stage IIC, alive, 490 days	85.2
TCGA-EB-A3HV-01A	37 years, male, white, stage:Stage IIC, alive, 39 days	77.0
TCGA-EB-A85J-01A	66 years, female, white, stage:Stage IIB, alive, 360 days	76.3
TCGA-EB-A6QZ-01A	76 years, female, white, stage:Stage IIA, dead, 352 days	76.0
TCGA-XV-A9W2-01A	81 years, male, white, stage:Stage I, alive, 417 days	75.5
TCGA-BF-AAOX-01A	83 years, male, white, stage:Stage IIC, alive, 444 days	75.4
TCGA-BF-A5EQ-01A	63 years, male, white, stage:Stage IIC, alive, 323 days	74.4
TCGA-GN-A8LN-01A	68 years, male, white, stage:Stage IIC, alive, 772 days	74.4
TCGA-EB-A550-01A	75 years, female, white, stage:Stage IIC, dead, 264 days	72.5
TCGA-BF-AAP2-01A	62 years, male, white, stage:Stage IIB, alive, 405 days	70.6
TCGA-EB-A97M-01A	66 years, male, white, stage:Stage IIC, alive, 414 days	70.2
TCGA-BF-AAP4-01A	61 years, male, white, stage:Stage IIC, alive, 335 days	68.5
TCGA-GN-A26C-01A	77 years, male, white, stage:Stage IIIC, dead, 821 days	67.2
TCGA-EB-A42Z-01A	49 years, male, asian, stage:Stage IIIC, alive, 441 days	65.6
TCGA-GN-A4U5-01A	61 years, female, white, stage:Stage IB, alive, 1156 days	65.5
TCGA-WE-A8K4-01A	85 years, male, white, stage:Stage IIB, alive, 614 days	64.7
TCGA-EB-A42Y-01A	73 years, female, asian, stage:Stage IIC, dead, 721 days	64.3
TCGA-EB-A82B-01A	58 years, female, asian, stage:Stage III, alive, 390 days	63.2
TCGA-BF-AAP8-01A	58 years, male, white, stage:Stage IIC, alive, 447 days	62.0
TCGA-EB-A1NK-01A	48 years, male, white, stage:Stage IIC, alive, 1039 days	62.0
TCGA-XV-AAZV-01A	56 years, female, white, stage:Stage II, alive, 412 days	61.5
TCGA-ER-A2NF-01A	53 years, male, white, stage:Stage IIIB, dead, 877 days	61.2
TCGA-FR-A728-01A	54 years, female, white, stage:Stage IIIB, alive, 583 days	61.0
TCGA-EB-A4XL-01A	56 years, female, white, stage:Stage IIC, alive, 777 days	60.1
TCGA-EB-A3Y6-01A	56 years, female, white, stage:Stage IIC, alive, 126 days	57.4
TCGA-BF-A9VF-01A	77 years, male, white, stage:Stage IIC, alive, 440 days	57.4
TCGA-YG-AA3N-01A	67 years, male, stage:Stage IIC, alive, 306 days	56.7
TCGA-BF-A3DL-01A	84 years, female, white, stage:Stage IIIB, alive, 769 days	55.6
TCGA-EB-A57M-01A	56 years, male, asian, stage:Stage IIIB, dead, 472 days	52.7
TCGA-D9-A4Z3-01A	73 years, female, white, stage:Stage IIIC, alive, 505 days	50.3
TCGA-EB-A4P0-01A	82 years, male, white, stage:Stage IIC, dead, 326 days	49.8
TCGA-XV-AAZW-01A	62 years, female, white, stage:Stage II, dead, 393 days	48.7
TCGA-EB-A41B-01A	76 years, female, white, stage:Stage IIC, alive, 291 days	48.3
TCGA-EB-A299-01A	63 years, male, white, stage:Stage IIA, alive, 378 days	48.2
TCGA-EB-A4IQ-01A	42 years, female, asian, stage:Stage IIIB, dead, 636 days	46.8
TCGA-EB-A3XD-01A	53 years, female, white, stage:Stage IIC, alive, 1160 days	46.1
TCGA-IH-A3EA-01A	61 years, male, white, stage:Stage IIC, alive, 524 days	45.2
TCGA-EB-A85I-01A	66 years, male, white, stage:Stage IIC, alive, 362 days	37.8
TCGA-ER-A194-01A	77 years, male, white, stage:'--, dead, 1354 days	37.6
TCGA-XV-A9W5-01A	51 years, male, white, stage:Not Reported, alive, 392 days	37.6
TCGA-EB-A5UM-01A	48 years, female, white, stage:Stage IIC, alive, 779 days	37.4
TCGA-BF-A5EO-01A	65 years, male, white, stage:Stage IIC, alive, 703 days	34.9
TCGA-BF-AAOU-01A	73 years, female, white, stage:Stage IIC, alive, 476 days	34.0
TCGA-EB-A3XE-01A	77 years, female, white, stage:Stage IIA, alive, 180 days	31.0
TCGA-BF-A5ER-01A	63 years, male, white, stage:Stage IIC, alive, 327 days	28.0
TCGA-D3-A5GT-01A	43 years, male, white, stage:Stage IIIC, alive, 487 days	27.6
TCGA-EB-A5SF-01A	78 years, female, white, stage:Stage IIC, dead, 369 days	23.9
TCGA-EB-A4OY-01A	65 years, female, white, stage:Stage IIIB, alive, 977 days	22.0
TCGA-XV-AAZY-01A	76 years, female, white, stage:Stage IIIC, alive, 405 days	20.9
TCGA-ER-A2NB-01A	57 years, male, white, stage:Stage IIIB, dead, 857 days	19.9
TCGA-EB-A3Y7-01A	86 years, female, white, stage:Stage IIIB, dead, 326 days	17.3
TCGA-EB-A4OZ-01A	41 years, female, white, stage:Stage IIIC, alive, 620 days	16.3
TCGA-EB-A553-01A	62 years, male, white, stage:Stage IIC, alive, 226 days	11.1
TCGA-DA-A960-01A	73 years, male, white, stage:Stage IIB, alive, 804 days	9.5
Show allShow less

MELANOMA - Protein expressionⁱ A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

Antibody stainingⁱ Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells. Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample. Ascending and descending describe two types of gradient, based on difference in staining intensity between enterocytes in crypts and apical enterocytes. Ascending - the staining intensity is stronger in apical enterocytes (towards the lumen) compared to enterocytes in the crypts (gland based) Descending - the staining is weaker in apical enterocytes compared to enterocytes in crypts	Antibody HPA011276		Antibody HPA017062
Staining
High
Medium
Low
Not detected
Intensity
Strong
Moderate
Weak
Negative
Quantity
>75%
75%-25%
<25%
None
Location
Nuclear
Cytoplasmic/membranous
Cytoplasmic/membranous,nuclear
None
Malignant melanoma, NOS
Malignant melanoma, Metastatic site

Contact

The Project

The Human Protein Atlas

The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.

contact@proteinatlas.org